

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/03/31	2020/12/31	2020/03/31
<b>Balance Sheet</b>			
<b>Current assets</b>			
Cash and cash equivalents	892,489	291,141	377,089
Current financial assets at amortised cost	1,200	1,200	9,710
Current contract assets	117,659	101,779	69,200
Accounts receivable, net	84,582	66,947	39,452
Accounts receivable due from related parties, net	6,361	305	3,193
Other receivables	27,846	5,511	7,685
Current inventories	134,585	84,852	58,496
Prepayments	36,697	23,817	21,434
Other current assets	1,449	958	2,783
<b>Total current assets</b>	<b>1,302,868</b>	<b>576,510</b>	<b>589,042</b>
<b>Non-current assets</b>			
Non-current financial assets at fair value through other comprehensive income	158,180	191,810	109,461
Property, plant and equipment	784,111	690,078	534,068
Right-of-use assets	95,036	96,653	48,730
Intangible assets	57,215	60,641	70,787
Deferred tax assets	83,530	83,450	80,736
Other non-current assets	114,388	53,411	23,903
<b>Total non-current assets</b>	<b>1,292,460</b>	<b>1,176,043</b>	<b>867,685</b>
<b>Total assets</b>	<b>2,595,328</b>	<b>1,752,553</b>	<b>1,456,727</b>
<b>Current liabilities</b>			
Current borrowings	0	100,000	100,000
Current contract liabilities	85,273	125,904	138,016
Accounts payable	68,441	40,314	28,674
Other payables	200,294	132,326	58,951
Current tax liabilities	1,595	645	0
Current lease liabilities	23,370	24,325	14,142
Other current liabilities	979	1,265	820
<b>Total current liabilities</b>	<b>379,952</b>	<b>424,779</b>	<b>340,603</b>
<b>Non-current liabilities</b>			
Deferred tax liabilities	6,163	6,681	512
Non-current lease liabilities	71,751	72,282	33,701
Other non-current liabilities	37,376	37,144	37,375
<b>Total non-current liabilities</b>	<b>115,290</b>	<b>116,107</b>	<b>71,588</b>
<b>Total liabilities</b>	<b>495,242</b>	<b>540,886</b>	<b>412,191</b>
<b>Share capital</b>			
Ordinary share	1,532,536	1,282,377	1,279,545
Advance receipts for share capital	28	499	0
<b>Total Share Capital</b>	<b>1,532,564</b>	<b>1,282,876</b>	<b>1,279,545</b>
<b>Capital surplus</b>			
<b>Total capital surplus</b>	<b>569,030</b>	<b>53,113</b>	<b>261,090</b>
<b>Retained earnings</b>			
Unappropriated retained earnings (accumulated deficit)	-76,004	-207,233	-494,914
<b>Total retained earnings</b>	<b>-76,004</b>	<b>-207,233</b>	<b>-494,914</b>
<b>Other equity interest</b>			
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	74,496	82,911	-1,185
<b>Total other equity interest</b>	<b>74,496</b>	<b>82,911</b>	<b>-1,185</b>
<b>Total equity</b>	<b>2,100,086</b>	<b>1,211,667</b>	<b>1,044,536</b>
<b>Total liabilities and equity</b>	<b>2,595,328</b>	<b>1,752,553</b>	<b>1,456,727</b>
Equivalent issue shares of advance receipts for ordinary share	900	15,900	0
Number of shares in entity held by entity and by its subsidiaries	0	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/01/01To2021/03/31	2020/01/01To2020/03/31
<b>Income Statement</b>		
Total operating revenue	292,217	69,861
Total operating costs	126,212	61,917
Gross profit (loss) from operations	166,005	7,944
Gross profit (loss) from operations	166,005	7,944
Operating expenses		
Selling expenses	10,059	8,764
Administrative expenses	18,414	9,808
Research and development expenses	20,843	14,971
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	2,011	324
Total operating expenses	51,327	33,867
Net operating income (loss)	114,678	-25,923
Non-operating income and expenses		
Total interest income	27	602
Total other income	335	990
Other gains and losses, net	694	2,809
Finance costs, net	477	563
Total non-operating income and expenses	579	3,838
Profit (loss) from continuing operations before tax	115,257	-22,085
Total tax expense (income)	871	-482
Profit (loss) from continuing operations	114,386	-21,603
Profit (loss)	114,386	-21,603
Other comprehensive income		
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	7,909	-39,844
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-519	-3,848
Components of other comprehensive income that will not be reclassified to profit or loss	8,428	-35,996
Total other comprehensive income	8,428	-35,996
Total comprehensive income	122,814	-57,599
Basic earnings per share		
Total basic earnings per share	0.85	-0.17
Diluted earnings per share		
Total diluted earnings per share	0.85	-0.17

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2021/01/01To2021/03/31	2020/01/01To2020/03/31
<b>Statements of Cash Flows</b>		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	115,257	-22,085
Profit (loss) before tax	115,257	-22,085
Depreciation expense	34,465	27,745
Amortization expense	4,173	4,063
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	2,011	324
Interest expense	477	563
Interest income	-27	-602
Share-based payments	4,983	182
Impairment loss on non-financial assets	-10,594	326
Other adjustments to reconcile profit (loss)	0	-5
Total adjustments to reconcile profit (loss)	35,488	32,596
Decrease (increase) in contract assets	-15,880	-46,533
Decrease (increase) in accounts receivable	-19,685	53,292
Decrease (increase) in accounts receivable due from related parties	-6,056	7,451
Decrease (increase) in other receivable	-4,996	-5,717
Decrease (increase) in inventories	-39,139	-2,699
Decrease (increase) in prepayments	-12,880	2,808
Adjustments for decrease (increase) in other current assets	-491	5,221
Total changes in operating assets	-99,127	13,823
Increase (decrease) in contract liabilities	-40,631	46,330
Increase (decrease) in accounts payable	28,127	3,975
Increase (decrease) in other payable	613	-21,235
Adjustments for increase (decrease) in other current liabilities	-286	220
Increase (decrease) in net defined benefit liability	-6	-10
Total changes in operating liabilities	-12,183	29,280
Total changes in operating assets and liabilities	-111,310	43,103
Total adjustments	-75,822	75,699
Cash inflow (outflow) generated from operations	39,435	53,614
Interest paid	-921	-242
Income taxes refund (paid)	0	-40
Net cash flows from (used in) operating activities	38,514	53,332
Cash flows from (used in) investing activities		
Proceeds from disposal of financial assets at amortised cost	0	75,050
Proceeds from disposal of financial assets at fair value through profit or loss	24,239	0
Acquisition of property, plant and equipment	-52,193	-18,014
Increase in refundable deposits	0	330
Acquisition of intangible assets	-747	0
Increase in prepayments for business facilities	-62,152	-10,742
Interest received	27	464
Other investing activities	0	-13,100
Net cash flows from (used in) investing activities	-90,826	33,988
Cash flows from (used in) financing activities		
Increase in short-term loans	0	100,000
Decrease in short-term loans	-100,000	0
Proceeds from long-term debt	0	0
Payments of lease liabilities	-6,962	-3,902
Proceeds from issuing shares	760,594	0
Exercise of employee share options	28	0
Net cash flows from (used in) financing activities	653,660	96,098
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	601,348	183,418
Cash and cash equivalents at beginning of period	291,141	193,671
Cash and cash equivalents at end of period	892,489	377,089
Cash and cash equivalents reported in the statement of financial position	892,489	377,089
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

**2021/03/31 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Advance receipts for share capital	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,282,377	499	1,282,876	53,113	-207,233	-207,233	82,911	82,911		1,211,667
Profit (loss)	0	0	0	0	114,386	114,386	0	0		114,386
Other comprehensive income	0	0	0	0	0	0	8,428	8,428		8,428
Total comprehensive income	0	0	0	0	114,386	114,386	8,428	8,428		122,814
Issue of shares	250,000	0	250,000	510,594	0	0	0	0		760,594
Share-based payments	0	0	0	4,983	0	0	0	0		4,983
Disposal of investments in equity instruments designated at fair value through other comprehensive income	0	0	0	0	16,843	16,843	-16,843	-16,843		0
Others	159	-471	-312	340	0	0	0	0		28
Total increase (decrease) in equity	250,159	-471	249,688	515,917	131,229	131,229	-8,415	-8,415		888,419
Equity at end of period	1,532,536	28	1,532,564	569,030	-76,004	-76,004	74,496	74,496		2,100,086

**2020/03/31 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,279,545	1,279,545	260,908	-473,311	-473,311	34,811	34,811		1,101,953
Profit (loss)	0	0	0	-21,603	-21,603	0	0		-21,603
Other comprehensive income	0	0	0	0	0	-35,996	-35,996		-35,996
Total comprehensive income	0	0	0	-21,603	-21,603	-35,996	-35,996		-57,599
Issue of shares	0	0	0	0	0	0	0		0
Share-based payments	0	0	182	0	0	0	0		182
Total increase (decrease) in equity	0	0	182	-21,603	-21,603	-35,996	-35,996		-57,417
Equity at end of period	1,279,545	1,279,545	261,090	-494,914	-494,914	-1,185	-1,185		1,044,536